1. 1) Food and Drug Administration. “FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR).”: ‹https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin›, accessed 29 September, 2021.
2. 2) PMDA. “PMDA revises a label tofogliflozin. 9 Jan 2015.”: ‹https://www.info.pmda.go.jp/kaiteip/20150109A002/03.pdf›, accessed 29 September, 2021.
3. 3) PMDA. “PMDA revises labels ipragliflozin, dapagliflozin, luseogliflozin, canagliflozin, and empagliflozin.”: ‹https://www.info.pmda.go.jp/kaiteip/20150109A002/02.pdf›, accessed 29 September, 2021.
4. 4) The committee on the proper use of SI. “Recommendations 2016.5. on the proper use of SGLT2 inhibitors.”: ‹https://www.sagacde.gr.jp/cms/wp-content/uploads/2020/05/iryou20160512-1.pdf›, accessed 29 September, 2021.
5. 5) The Committee on the Proper Use of SI. “Recommendations 2019.8. on the proper use of SGLT2 inhibitors.”: ‹https://www.nittokyo.or.jp/uploads/files/recommendation_SGLT2_190806.pdf›, accessed 29 September, 2021.